State transition probabilities, depending on the efficacy of the treatments with respect to PFS were estimated through a survival analysis of patient-level data (Celgene data on file). Due to the potential of crossover/subsequent treatment options induced bias, OS was estimated using a quantitative relationship between PFS and OS from a censored normal weighted Tobit regression model, based on 153 MM studies containing 230 treatment arms 7 . In this study, Félix et all (2013) estimated that a 2.5 month (95% confidence interval, 1.7-3.2) increment in median OS is expected for each additional month in median PFS (Table 1) . 
patients at an acceptable incremental cost. Lenalidomide plus dexamethasone can be regarded a valuable treatment option for second or greater line therapy in multiple myeloma patients.
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